Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms
Artificial intelligence can optimize virus manufacturing for cancer vaccines at scales 100 times higher, potentially making novel immunotherapies more affordable and available.
Review of manufacturing advances for poxvirus-based viral vectors (cancer vaccines, oncolytic agents), highlighting AI-optimized bioprocessing that increases yields by 2 orders of magnitude over traditional adsorption chromatography. Relevant to AI in drug development and novel immunotherapy manufacturing scalability.
What the study was
- Study design
- Review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Expert Review of Vaccines
Why it surfaced
AI manufacturing optimization for cancer vaccine vectors; relevance is peripheral (manufacturing not clinical), score capped accordingly.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.